论文部分内容阅读
目的 分析二种不同特性产物在肿瘤中的表达及相互关系,检测数据进行统计学分析。方法 应用免疫组化方法对62例卵巢上皮性癌进行了ER、PR、C—erbB—2、P53检测。结果 ①ER、PR阳性表达率分别为70.96％(44/62)和67.74％(42/62)。②P53、C—erbB—2阳性表达率各为43.38％(30/62)和41.93％(26/62)。③高分化癌ER、PR阳性表达率高,P53、C—erbB—2阳性表达低,二者呈负相关(P<0.01)。④ER、PR阳性患者的P53、C—erbB—2阳性表达率低于ER、PR阴性患者,(P<0.05)。⑤获访者中ER、PR阴性组患者同时伴P53、C—erbB—2阳性表达的患者死亡率高。结论 ER、PR与P53、C—erbB—2二种不同产物在卵巢上皮性癌中有一定的内在联系,在检测性卵巢癌ER、PR的同时、检测P53、C—erbB—2可作为判断预后的综合指标。
Objective To analyze the expression and correlation of two different products in tumor and to make statistical analysis. Methods Immunohistochemistry was used to detect ER, PR, C-erbB-2 and P53 in 62 patients with epithelial ovarian cancer. Results ① The positive rates of ER and PR were 70.96% (44/62) and 67.74% (42/62) respectively. ② The positive rates of p53 and C-erbB-2 were 43.38% (30/62) and 41.93% (26/62) respectively. ③ The positive expression rate of ER and PR in well-differentiated carcinoma was high, while the positive expression of P53 and C-erbB-2 was low, both were negative correlation (P <0.01). ④ The positive rates of P53 and C-erbB-2 in ER and PR positive patients were lower than those in ER and PR negative patients (P <0.05). ⑤ The respondents in the ER, PR-negative patients with concurrent P53, C-erbB-2 expression in patients with high mortality. Conclusions ER, PR, P53 and C-erbB-2 are related to each other in epithelial ovarian cancer. Detecting the expression of P53 and C-erbB-2 in ovarian cancer while detecting ER and PR, Prognosis of the comprehensive index.